Position of the Transparency Council – Rubraca (rucaparib)
At its meeting on 27 January 2025, the Transparency Council adopted position No. 27/2025 on the evaluation of the drug Rubraca (rucaparib) under drug program B.50 “Treatment of patients with ovarian cancer, fallopian tube cancer or peritoneal cancer (ICD-10: C56, C57, C48)”